Business Wire

TREKSTOR

Share
blnk Healthcare Extend Portfolio of Respirators and Face Masks

With the end of the pandemic not in sight yet, TREKSTOR is announcing the expansion of its mask portfolio, therefore fulfilling the increased demand created by regulations and customers alike.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005568/en/

Some of the new entries are comprised of so-called filtering half-masks, commonly known as FFP2 and FFP3. The FFP2 masks with the model name BL-03N (item 30604) are packaged 2pcs per bag with the user manual directly printed on the outside. Comprised of 5 layers, the respirators have been type-approved by notified body SGS Fimko (0598) and are valid to use for 24 months from production. They are worn with ear-straps and come with a flexible nose guard included in the fabric.

Additionally, newly available are 20pcs boxes of two FFP3 masks with the model names LT-2020AP3 (item 30613) and LT-2020AP3V (item 30614), the later which includes a vent. Both masks are foldable, also include a nose-guard and are worn with elastic headbands, that can be adjusted to fit perfectly. Like all FFP3 masks, they filter ≥99% of particles, as has been confirmed by the notified body Applus (0370). This allows them to also be used in direct contact with COVID-19 positive patients.

„The demand for filtering half-masks has increased drastically over the last few weeks“ , says Shimon Szmigiel, CEO of TREKSTOR. „Therefore, we decided to expand our portfolio beyond the already available KN95 respirators with CE approval based on EU guideline PPE-R 02.075.“

At the same time the face mask portfolio was updated. While the focus always has been on EN 14683:2019 certified masks of both types IIR and I, they were always only available for adults. But now TREKSTOR also offers type IIR face masks for children as well.

„Type IIR face masks filter ≥98% of exhaled air, therefore offering good protection for everyone around“ , Simon Wiedemann, Head of Product Management explains. „With infections spreading in schools and day care centres more and more, wearing such masks consistently can help stop the spread of the virus dramatically.“

So kids can enjoy wearing a mask, TREKSTOR decided to offer them in 10 different designs, 5 each suited for boys and girls. Each design is packed 5pcs per re-sealable bag, if kids like to be surprised, the masks are also available in 5pcs mix packs with one mask of each design present within.

The kids masks are already in stock and can be ordered online at www.blnk-healthcare.com . The shop is also ready to accept pre-orders to FFP2 and FFP3 masks, which will then be fulfilled in early January. Interested parties can also declare their interest by sending an email to sales@blnk-healthcare.com . PR requests should be directed to pr@blnk-healthcare.com .

About TREKSTOR / blnk Healthcare

TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies and end-consumers.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye